Dissemin is shutting down on January 1st, 2025

Published in

Oxford University Press, Journal of Pharmacy and Pharmacology, 12(71), p. 1774-1783, 2019

DOI: 10.1111/jphp.13162

Links

Tools

Export citation

Search in Google Scholar

Thymol reverses depression‐like behaviour and upregulates hippocampal BDNF levels in chronic corticosterone‐induced depression model in female mice

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Abstract Objectives Based on this, the central therapeutic effects of thymol were verified in the neurotrophic pathway. Methods Female swiss mice were divided into four groups: control, corticosterone (Cort), thymol (Cort + thymol) and fluvoxamine (Cort + Flu). The administration of corticosterone was used to induce depressive symptoms for 23 days. After the treatment, the animals were exposed the behavioural tests, such as forced swimming test, tail suspension test, sucrose preference test, light/dark test, social interaction test, Y-maze test, plus-maze test and hole-board test. The hippocampus was also removed, and BDNF was measured by ELISA and Western blot. Key findings As a result, thymol and fluvoxamine were able to reverse the depressive symptoms, as well as to improve the anxious frame. The anhedonic and short-term memory was restored with the treatment. In the neurochemical tests, both thymol and fluvoxamine restored BDNF levels, improving the depressive condition. Conclusions This work opens up new investigations aiming at the use of this molecule as a therapeutic alternative for treating depression disorders.